



Product Information Sheet for HRP-11580

Maraviroc

Catalog No. HRP-11580

For research use only. Not for use in humans.

Contributor

Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID)

Manufacturer

Ambeed, Inc.

Product Description:

Maraviroc (brand name: Selzentry) is an entry inhibitor, specifically blocking the CCR5 chemokine receptor which is used by human immunodeficiency virus (HIV) as a coreceptor to bind and enter human helper T cells.^{1,2,3} Because HIV can also use another coreceptor, CXCR4, an HIV tropism test such as a trofile assay must be performed to determine if maraviroc will be effective.

HRP-11580 is highly soluble across a pH range of 1 to 7.5.

Material Provided:

Each vial contains approximately 20 mg of maraviroc.

Packaging/Storage:

HRP-11580 was packaged in amber glass vials and should be stored at 2°C to 8°C. Once resuspended, working aliquots can be stored at -20°C. The vial should be centrifuged prior to opening.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH HIV Reagent Program, NIAID, NIH: Maraviroc, HRP-11580, contributed by DAIDS/NIAID."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories](#). 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the NIH HIV Reagent Program Material Transfer Agreement

(MTA). The MTA is available on our Web site at www.hivreagentprogram.org.

While the NIH HIV Reagent Program uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to the NIH HIV Reagent Program are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Emmelkamp, J. M. and J. K. Rockstroh. "CCR5 Antagonists: Comparison of Efficacy, Side Effects, Pharmacokinetics and Interactions--Review of the Literature." [Eur. J. Med. Res.](#) 12 (2007): 409-417. PubMed: 17933722.
2. Biswas, P., G. Tambussi and A. Lazzarin. "Access Denied? The Status of Co-Receptor Inhibition to Counter HIV Entry." [Expert Opin. Pharmacother.](#) 8 (2007): 923-933. PubMed: 17472538.
3. Stephenson, J. "Researchers Buoyed by Novel HIV Drugs: Will Expand Drug Arsenal against Resistant Virus." [JAMA](#) 297 (2007): 1535-1536. PubMed: 17426263.

ATCC® is a trademark of the American Type Culture Collection.



NIH HIV Reagent Program

www.hivreagentprogram.org

E-mail: contact@HIVReagentProgram.org

Tel: 888-487-0727 | Fax: 703-365-2898

© 2022 American Type Culture Collection (ATCC)

All rights reserved.

HRP-11580_12JUL2022

Page 1 of 1